SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending as investors bet on the companys pivot from crypto mining to AI-focused data center infrastructure. The community is actively discussing rumors of imminent lease contracts and positive technical momentum, with many highlighting the potential for a rerating as the company integrates into major market indices.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest positive Phase 3 VELA-program data, which demonstrates durable efficacy and a clean safety profile for sonelokimab in treating hidradenitis suppurativa. The community is actively discussing the stock's best-in-class potential and the likelihood of a strategic buyout as the company moves toward BLA submission.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing significant market momentum following a multi-year joint research agreement with Honda, which validates the scalability and performance of its solid-state battery platform. Community sentiment is largely bullish, with investors actively discussing the company's expanding OEM ecosystem, potential applications in AI data centers, and the strategic importance of securing a second major automotive partner beyond Volkswagen.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following positive topline Phase 3 Emerge study results, which showed statistically significant and clinically meaningful improvement in major depressive disorder. Community discussion remains highly focused on the upcoming readouts for the company's GAD programs, with investors debating the stock's potential for a broader re-rate while weighing the ongoing risks of cash burn and future dilution.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as a primary beneficiary of the AI-driven memory supercycle, with the community actively debating whether its parabolic rise represents sustainable structural growth or a speculative bubble reminiscent of the dot-com era. Traders remain sharply divided between aggressive bulls targeting further highs and skeptics calling for a correction, while attention shifts toward upcoming earnings catalysts in the broader semiconductor sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant momentum as investors digest a positive analyst upgrade and anticipation builds for next month's FDA peptide review. The stock's recent breakout above key moving averages has the community actively debating whether this is the start of a sustained valuation re-rating or another cycle of volatility driven by heavy short interest.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is in the spotlight following the FDA's decision to issue a Complete Response Letter (CRL) for its Hunter syndrome gene therapy, NAVSUNLI, effectively rejecting the current application while demanding additional data. Investors are now shifting their focus toward the company's long-term pipeline potential, specifically the RGX-202 program for Duchenne muscular dystrophy and the ongoing wet AMD collaboration with AbbVie, as the community debates whether current valuations adequately reflect the company's remaining cash runway and development milestones.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron (CVX) is trending as investors weigh strong operational performance and dividend reliability against the geopolitical risks of the Strait of Hormuz conflict. The community is actively debating the stock's resilience, with many noting that persistent supply disruptions and energy security themes continue to act as key catalysts for the sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community interest as high volume and unusual pre-market activity fuel speculation regarding a potential buyout or upcoming catalyst for the AUR200 pipeline. Investors are closely monitoring CEO Kevin Tang's significant share accumulation while debating the impact of ongoing patent litigation and the strategic silence from the new management team.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as investors monitor a rotation into the biotech sector, fueled by anticipation of key clinical trial readouts and potential M&A activity despite broader market volatility. Community discourse remains heavily focused on the high-risk, high-reward profiles of individual companies like SLS and IBRX, with many users tracking short interest, pipeline milestones, and regulatory catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA approves $AMRX ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity. https://notreload.xyz/xy/fda-approves-amneal-ready-to-use-romidepsin-injection/

FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.

NOTRELOAD AI

FDA Approves Amneal's Ready-to-Use Romidepsin Injection

StockTwits Web

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

 ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity. 